{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:23:31Z","timestamp":1790205811653,"version":"4.1.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":1914,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A worsening renal function is prevalent among patients with cardiovascular disease, especially heart failure (HF). Sacubitril\/valsartan appears to prevent worsening of renal function and progression of chronic kidney disease (CKD) as compared with renin\u2013angiotensin system (RAS) inhibitors alone in HF patients. It is unclear whether these advantages are present in HF patients only, or can be extended to other categories of patients, in which this drug was studied. We performed a systematic review and meta-analysis to assess the consistency of effect size regarding renal outcome across randomized controlled trials (RCTs) that compared sacubitril\/valsartan with RAS inhibitors in patients with or without HF. We searched Medline (PubMed), Scopus, and Thomson Reuters Web of Science databases until June 2020. We took into account RCTs that compared sacubitril\/valsartan with a RAS inhibitor and reported data regarding renal function. We used random-effects models to obtain summary odds ratio (OR) with 95% confidence interval (CI). We extracted hazard ratios for renal outcomes, glomerular filtration rate slopes or rates of renal adverse events. Sensitivity analyses were performed by moderator analysis and random-effects meta-regression. The search revealed 10 RCTs (published between 2012 and 2019) on 16 456 subjects. Sacubitril\/valsartan resulted in a lower risk of renal dysfunction as compared with RAS inhibitors alone [k = 10; pooled OR = 0.70 (95% CI 0.57\u20130.85); P &amp;lt; 0.001], with a moderate inconsistency between studies [Q(9) = 15.18; P = 0.086; I2 = 40.73%]. A stronger association was found in studies including older patients (k = 10; \u03b2 = \u22120.047730; P = 0.020) or HF patients with preserved ejection fraction [pooled OR = 0.53 (0.41\u20130.68) vs. 0.76 (0.57\u20131.01) for studies on HF patients with reduced ejection fraction; P for comparison = 0.065]. The effect size did not change with different comparators (angiotensin-converting enzyme inhibitors vs. angiotensin II type 1 receptor blockers, P = 0.279). No significant association was found when the analysis was restricted to studies on non-HF patients [k = 3; pooled OR = 0.86 (0.61\u20131.22); P = 0.403] and studies with high risk of bias [k = 3; pooled OR = 0.34 (0.08\u20131.44); P = 0.143]. Our findings support the role of sacubitril\/valsartan on preservation of renal function, especially in older patients and HF patients with preserved ejection fraction. However, evidence is currently limited to HF patients, while the renal outcome of sacubitril\/valsartan therapy outside the HF setting needs to be further investigated.<\/jats:p>","DOI":"10.1002\/ehf2.13002","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T10:56:49Z","timestamp":1600772209000},"page":"3487-3496","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Effect of Sacubitril\/Valsartan on Renal Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1093","volume":"7","author":[{"given":"Francesco","family":"Spannella","sequence":"first","affiliation":[{"name":"Internal Medicine and Geriatrics, IRCCS INRCA , Via della Montagnola 81, Ancona ,","place":["Italy"]},{"name":"Department of Clinical and Molecular Sciences, University \u2018Politecnica delle Marche\u2019 , Via Tronto 10\/a, Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Giulietti","sequence":"additional","affiliation":[{"name":"Internal Medicine and Geriatrics, IRCCS INRCA , Via della Montagnola 81, Ancona ,","place":["Italy"]},{"name":"Department of Clinical and Molecular Sciences, University \u2018Politecnica delle Marche\u2019 , Via Tronto 10\/a, Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Filipponi","sequence":"additional","affiliation":[{"name":"Internal Medicine and Geriatrics, IRCCS INRCA , Via della Montagnola 81, Ancona ,","place":["Italy"]},{"name":"Department of Clinical and Molecular Sciences, University \u2018Politecnica delle Marche\u2019 , Via Tronto 10\/a, Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5159-0181","authenticated-orcid":false,"given":"Riccardo","family":"Sarzani","sequence":"additional","affiliation":[{"name":"Internal Medicine and Geriatrics, IRCCS INRCA , Via della Montagnola 81, Ancona ,","place":["Italy"]},{"name":"Department of Clinical and Molecular Sciences, University \u2018Politecnica delle Marche\u2019 , Via Tronto 10\/a, Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"2026012115024139400_ehf213002-bib-0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS ONE"},{"key":"2026012115024139400_ehf213002-bib-0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Collaboration GBDCKD","year":"2020","journal-title":"Lancet"},{"key":"2026012115024139400_ehf213002-bib-0003","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1001\/archinte.166.17.1884","article-title":"Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control","volume":"166","author":"Parikh","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026012115024139400_ehf213002-bib-0004","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012115024139400_ehf213002-bib-0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012115024139400_ehf213002-bib-0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2026012115024139400_ehf213002-bib-0007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1172\/JCI101720","article-title":"Edema and decreased renal blood flow in patients with chronic congestive heart failure: evidence of \u201cforward failure\u201d as the primary cause of edema","volume":"25","author":"Merrill","year":"1946","journal-title":"J Clin Invest"},{"key":"2026012115024139400_ehf213002-bib-0008","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115024139400_ehf213002-bib-0009","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2026012115024139400_ehf213002-bib-0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Failure"},{"key":"2026012115024139400_ehf213002-bib-0011","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115024139400_ehf213002-bib-0012","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11739-019-02111-6","article-title":"Renal effects of sacubitril\/valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study","volume":"14","author":"Spannella","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2026012115024139400_ehf213002-bib-0013","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER Study","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"2026012115024139400_ehf213002-bib-0014","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2026012115024139400_ehf213002-bib-0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijcard.2019.05.048","article-title":"Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: a meta-analysis of randomized controlled trials","volume":"293","author":"Geng","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026012115024139400_ehf213002-bib-0016","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026012115024139400_ehf213002-bib-0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2026012115024139400_ehf213002-bib-0018","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"2026012115024139400_ehf213002-bib-0019","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012115024139400_ehf213002-bib-0020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115024139400_ehf213002-bib-0021","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026012115024139400_ehf213002-bib-0022","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2026012115024139400_ehf213002-bib-0023","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2026012115024139400_ehf213002-bib-0024","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/ajh\/hpx111","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (&gt;\/=65 years) with systolic hypertension","volume":"30","author":"Supasyndh","year":"2017","journal-title":"Am J Hypertens"},{"key":"2026012115024139400_ehf213002-bib-0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jch.13153","article-title":"Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study","volume":"20","author":"Cheung","year":"2018","journal-title":"J Clin Hypertens"},{"key":"2026012115024139400_ehf213002-bib-0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril\u2013valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"2026012115024139400_ehf213002-bib-0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1536\/ihj.19-231","article-title":"The impact of sacrubitril\/valsartan on clinical treatment and hs-cTnT and NT-proBNP serum levels and the left ventricular function in patients with chronic heart failure","volume":"61","author":"Gao","year":"2020","journal-title":"Int Heart J"},{"key":"2026012115024139400_ehf213002-bib-0028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115024139400_ehf213002-bib-0029","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"key":"2026012115024139400_ehf213002-bib-0030","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/CIRCULATIONAHA.118.036523","article-title":"Neprilysin inhibition and effects on kidney function and surrogates of cardiovascular risk in chronic kidney disease","volume":"138","author":"James","year":"2018","journal-title":"Circulation"},{"key":"2026012115024139400_ehf213002-bib-0031","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin\u2013angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diab Endocrinol"},{"key":"2026012115024139400_ehf213002-bib-0032","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ajh.2008.174","article-title":"Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases","volume":"21","author":"Rubattu","year":"2008","journal-title":"Am J Hypertens"},{"key":"2026012115024139400_ehf213002-bib-0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/ijms20020245","article-title":"PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides","volume":"20","author":"Bordicchia","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026012115024139400_ehf213002-bib-0034","doi-asserted-by":"crossref","first-page":"19178","DOI":"10.1038\/s41598-019-55680-z","article-title":"Association between cardiac natriuretic peptides and lipid profile: a systematic review and meta-analysis","volume":"9","author":"Spannella","year":"2019","journal-title":"Sci Rep"},{"key":"2026012115024139400_ehf213002-bib-0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40292-017-0196-1","article-title":"Cardiac natriuretic peptides, hypertension and cardiovascular risk","volume":"24","author":"Sarzani","year":"2017","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2026012115024139400_ehf213002-bib-0036","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3390\/ijms20112629","article-title":"Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications","volume":"20","author":"Tanase","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026012115024139400_ehf213002-bib-0037","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","article-title":"Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications?","volume":"90","author":"Malek","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2026012115024139400_ehf213002-bib-0038","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1523-1755.2001.060002715.x","article-title":"Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats","volume":"60","author":"Cao","year":"2001","journal-title":"Kidney Int"},{"key":"2026012115024139400_ehf213002-bib-0039","first-page":"R1457","article-title":"Renal and vascular effects of C-type and atrial natriuretic peptides in humans","volume":"273","author":"Pham","year":"1997","journal-title":"Am J Physiol"},{"key":"2026012115024139400_ehf213002-bib-0040","first-page":"F63","article-title":"Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans","volume":"274","author":"Jensen","year":"1998","journal-title":"Am J Physiol"},{"key":"2026012115024139400_ehf213002-bib-0041","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.3390\/ijms20143581","article-title":"BNP as a major player in the heart\u2013kidney connection","volume":"20","author":"Okamoto","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026012115024139400_ehf213002-bib-0042","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","article-title":"Effect of neprilysin inhibition on various natriuretic peptide assays","volume":"73","author":"Ibrahim","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012115024139400_ehf213002-bib-0043","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1373\/clinchem.2016.262907","article-title":"Biochemistry, therapeutics, and biomarker implications of neprilysin in cardiorenal disease","volume":"63","author":"Chen","year":"2017","journal-title":"Clin Chem"},{"key":"2026012115024139400_ehf213002-bib-0044","first-page":"F615","article-title":"Renal and systemic effects of urodilatin in rats with high-output heart failure","volume":"262","author":"Abassi","year":"1992","journal-title":"Am J Physiol"},{"key":"2026012115024139400_ehf213002-bib-0045","first-page":"30223","article-title":"Sodium-glucose co-transporter-2 inhibitors: peculiar \u201chybrid\u201d diuretics that protect from target organ damage and cardiovascular events","volume":"S0939\u20134753","author":"Sarzani","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026012115024139400_ehf213002-bib-0046","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1042\/CS20160197","article-title":"Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone","volume":"130","author":"Roksnoer","year":"2016","journal-title":"Clin Sci"},{"key":"2026012115024139400_ehf213002-bib-0047","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-019-0847-8","article-title":"The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker obese rat","volume":"18","author":"Habibi","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2026012115024139400_ehf213002-bib-0048","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/01.hjh.0000179765.48324.b4","article-title":"Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto\u2013Kakizaki rats","volume":"23","author":"Cheng","year":"2005","journal-title":"J Hypertens"},{"key":"2026012115024139400_ehf213002-bib-0049","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ndt\/gfu269","article-title":"Neprilysin inhibition in chronic kidney disease","volume":"30","author":"Judge","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2026012115024139400_ehf213002-bib-0050","first-page":"5473","article-title":"LCZ696 (sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD","volume":"9","author":"Jing","year":"2017","journal-title":"Am J Trans Res"},{"key":"2026012115024139400_ehf213002-bib-0051","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/ijms19041006","article-title":"Particulate guanylyl cyclase A\/cGMP signaling pathway in the kidney: physiologic and therapeutic indications","volume":"19","author":"Chen","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026012115024139400_ehf213002-bib-0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108954","article-title":"The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet","volume":"116","author":"Yang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2026012115024139400_ehf213002-bib-0053","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ejhf.267","article-title":"Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?","volume":"17","author":"Ruggenenti","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012115024139400_ehf213002-bib-0054","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1172\/JCI113120","article-title":"Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration","volume":"80","author":"Ortola","year":"1987","journal-title":"J Clin Invest"},{"key":"2026012115024139400_ehf213002-bib-0055","first-page":"F415","article-title":"Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles","volume":"255","author":"Ohishi","year":"1988","journal-title":"Am J Physiol"},{"key":"2026012115024139400_ehf213002-bib-0056","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/eurheartj\/ehr242","article-title":"Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney","volume":"32","author":"Ruggenenti","year":"2011","journal-title":"Eur Heart J"},{"key":"2026012115024139400_ehf213002-bib-0057","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jchf.2018.02.017","article-title":"Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure","volume":"6","author":"Mullens","year":"2018","journal-title":"JACC Heart failure"},{"key":"2026012115024139400_ehf213002-bib-0058","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2362.1999.00422.x","article-title":"Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption","volume":"29","author":"Jacobs","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"2026012115024139400_ehf213002-bib-0059","first-page":"1","article-title":"Cardiac natriuretic peptides","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13002","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3487\/65902298\/eschf_7_6_3487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3487\/65902298\/eschf_7_6_3487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:02:59Z","timestamp":1769025779000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/6\/3487\/8372468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,9,22]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13002","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,22]]},"assertion":[{"value":"2020-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}